Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Calcitriol, the bioactive metabolite of vitamin D, increases ventricular K+ currents in isolated mouse cardiomyocytes

  • Tamayo, María
  • Martín-Nunes, Laura
  • Val-Blasco, Almudena
  • Piedras, Maria J.
  • Larriba, María Jesús
  • Gómez-Hurtado, Nieves
  • Fernández-Velasco, María
  • Delgado, Carmen
Calcitriol, the bioactive metabolite of vitamin D, interacts with the ubiquitously expressed nuclear vitamin D receptor (VDR) to induce genomic effects, but it can also elicit rapid responses via membrane-associated VDR through mechanisms that are poorly understood. The down-regulation of K+ currents is the main origin of electrophysiological remodeling in pathological hypertrophy and heart failure (HF), which can contribute to action potential prolongation and subsequently increase the risk of triggered arrhythmias. Adult mouse ventricular myocytes were isolated and treated with 10 nM calcitriol or vehicle for 15-30 min. In some experiments, cardiomyocytes were pretreated with the Akt inhibitor triciribine. In the adult mouse ventricle, outward K+ currents involved in cardiac repolarization are comprised of three components: the fast transient outward current (Itof), the ultrarapid delayed rectifier K+ current (Ikur), and the non-inactivating steady-state outward current (Iss). K+ currents were investigated using the whole-cell or the perforated patch-clamp technique and normalized to cell capacitance to obtain current densities. Calcitriol treatment of cardiomyocytes induced an increase in the density of Itof and Ikur, which was lost in myocytes isolated from VDR-knockout mice. In addition, calcitriol activated Akt in cardiomyocytes and pretreatment with triciribine prevented the calcitriol-induced increase of outward K+ currents. In conclusion, we demonstrate that calcitriol via VDR and Akt increases both Itof and Ikur densities in mouse ventricular cardiomyocytes. Our findings may provide new mechanistics clues for the cardioprotective role of this hormone in the heart., This work was supported by grants SAF2014-57190R, SAF2017-84777R, and SAF2016-76377R from the Spanish Ministerio de Industria, Economia y Competitividad and PI14/01078 and PI17/01344 from ISCIII, Fondos FEDER and CIBER-CV and CIBERONC, networks funded by ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deficiency of NOD1 improves the β-adrenergic modulation of Ca2+ handling in a mouse model of heart failure

  • Val-Blasco, Almudena
  • Navarro-García, Jose A.
  • Tamayo, María
  • Piedras, Maria J.
  • Prieto, Patricia
  • Delgado, Carmen
  • Ruiz-Hurtado, Gema
  • Rozas-Romero, Laura
  • Gil-Fernández, Marta
  • Zaragoza, Carlos
  • Boscá, Lisardo
  • Fernández-Velasco, María
Heart failure (HF) is a complex syndrome characterized by cardiac dysfunction, Ca2+ mishandling, and chronic activation of the innate immune system. Reduced cardiac output in HF leads to compensatory mechanisms via activation of the adrenergic nervous system. In turn, chronic adrenergic overstimulation induces pro-arrhythmic events, increasing the rate of sudden death in failing patients. Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) is an innate immune modulator that plays a key role in HF progression. NOD1 deficiency in mice prevents Ca2+ mishandling in HF under basal conditions, but its role during β-adrenergic stimulation remains unknown. Here, we evaluated whether NOD1 regulates the β-adrenergic modulation of Ca2+ signaling in HF. Ca2+ dynamics were examined before and after isoproterenol perfusion in cardiomyocytes isolated from healthy and from post-myocardial infarction (PMI) wild-type (WT) and Nod1-/- mice. Isoproterenol administration induced similar effects on intracellular [Ca2+]i transients, cell contraction, and sarcoplasmic reticulum (SR)-Ca2+ load in healthy WT and Nod1-/- cells. However, compared with WT-PMI cells, isoproterenol exposure induced a significant increase in the [Ca2+]i transients and cell contraction parameters in Nod1-/--PMI cells, which mainly due to an increase in SR-Ca2+ load. NOD1 deficiency also prevented the increase in diastolic Ca2+ leak (Ca2+ waves) induced by isoproterenol in PMI cells. mRNA levels of β1 and β2 adrenergic receptors were significantly higher in Nod1-/--PMI hearts vs WT-PMI hearts. Healthy cardiomyocytes pre-treated with the selective agonist of NOD1, iE-DAP, and perfused with isoproterenol showed diminished [Ca2+]i transients amplitude, cell contraction, and SR-Ca2+ load compared with vehicle-treated cells. iE-DAP-treated cells also presented increased diastolic Ca2+ leak under β-adrenergic stimulation. The selectivity of iE-DAP on Ca2+ handling was validated by pre-treatment with the inactive analog of NOD1, iE-Lys. Overall, our data establish that NOD1 deficiency improves the β-adrenergic modulation of Ca2+ handling in failing hearts., MF-V is Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). This work was supported by grants PI14/01078, CP15/00129, PI17/01093, and PI17/01344 from ISCIII, Fondo Europeo de Desarrollo Regional (FEDER Ministerio de Economía y Competitividad of Spain (SAF2014-57190-R; SAF2017-84777-R), FSE, and CIBER-CV, a network funded by ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes

  • Navarro-García, Jose A.
  • Delgado, Carmen
  • Fernández-Velasco, María
  • Val-Blasco, Almudena
  • Rodríguez-Sánchez, Elena
  • Aceves‑Ripoll, Jennifer
  • Gómez-Hurtado, Nieves
  • Bada-Bosch, Teresa
  • Mérida-Herrero, Evangelina
  • Hernández, Eduardo
  • Praga, Manuel
  • Salguero, Rafael
  • Solís, Jorge
  • Arribas, Fernando
  • Delgado, Juan F.
  • Bueno, Héctor
  • Kuro-o, Makoto
  • Ruilope, Luis M.
  • Ruiz-Hurtado, Gema
[Background]: Cardiac dysfunction and arrhythmia are common and onerous cardiovascular events in end-stage renal disease (ESRD) patients, especially those on dialysis. Fibroblast growth factor (FGF)-23 is a phosphate-regulating hormone whose levels dramatically increase as renal function declines. Beyond its role in phosphorus homeostasis, FGF-23 may elicit a direct effect on the heart. Whether FGF-23 modulates ventricular cardiac rhythm is unknown, prompting us to study its role on excitation–contraction (EC) coupling., [Methods]: We examined FGF-23 in vitro actions on EC coupling in adult rat native ventricular cardiomyocytes using patch clamp and confocal microscopy and in vivo actions on cardiac rhythm using electrocardiogram., [Results]: Compared with vehicle treatment, FGF-23 induced a significant decrease in rat cardiomyocyte contraction, L-type Ca2+ current, systolic Ca2+ transients and sarcoplasmic reticulum (SR) load and SR Ca2+-adenosine triphosphatase 2a pump activity. FGF-23 induced pro-arrhythmogenic activity in vitro and in vivo as automatic cardiomyocyte extracontractions and premature ventricular contractions. Diastolic spontaneous Ca2+ leak (sparks and waves) was significantly increased by FGF-23 via the calmodulin kinase type II (CaMKII)-dependent pathway related to hyperphosphorylation of ryanodine receptors at the CaMKII site Ser2814. Both contraction dysfunction and spontaneous pro-arrhythmic Ca2+ events induced by FGF-23 were blocked by soluble Klotho (sKlotho)., [Conclusions]: Our results show that FGF-23 reduces contractility and enhances arrhythmogenicity through intracellular Ca2+ mishandling. Blocking its actions on the heart by improving sKlotho bioavailability may enhance cardiac function and reduce arrhythmic events frequently observed in ESRD., This work was supported by grants from the Spanish Institute of Health Carlos III (PIE13/00045, PI14/01841, CP15/00129, PI17/01093, PI17/01193, PI14/01078, PI17/01344, MSII16/00047), Fundación SENEFRO/Sociedad Española de Nefrología (SEN), Sociedad Española de Cardiología (SEC), Luis Hernando Project from Fundación Íñigo Álvarez de Toledo (FRIAT) and Fondo Europeo de Desarrollo Regional (Fondos FEDER) and Ministerio de Economía, Industria y Competitividad (SAF2014-57190-R, SAF2017-84777-R). Jennifer Aceves-Ripoll was funded by Comunidad de Madrid [Programa Operativo de Empleo Juvenil y la Iniciativa de Empleo Juvenil (YEI) 2015]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure

  • Tamayo, María
  • Martín-Nunes, Laura
  • Val-Blasco, Almudena
  • Piedras, Maria J.
  • Navarro-García, Jose A.
  • Lage, Eduardo
  • Prieto, Patricia
  • Ruiz-Hurtado, Gema
  • Fernández-Velasco, María
  • Delgado, Carmen
[Background and Purpose]: The synthetic vitamin D3 analogue paricalcitol acts as a selective activator of the vitamin D receptor (VDR). While there is evidence for cardioprotective effects of paricalcitol associated with the VDR pathway, less information is available about the structural and functional cardiac effects of paricalcitol on established heart failure (HF) and particularly its effects on associated electrophysiological or Ca2+ handling remodelling., [Experimental Approach]: We used a murine model of transverse aortic constriction (TAC) to study the effect of paricalcitol on established HF. Treatment was initiated 4 weeks after surgery over five consecutive weeks, and mice were sacrificed 9 weeks after surgery. Cardiac MRI (CMRI) was performed 4 and 9 weeks after surgery. Hearts were used for biochemical and histological studies and to isolate ventricular myocytes for electrophysiological and calcium imaging studies., [Key Results]: CMRI analysis revealed that, compared with vehicle, paricalcitol treatment prevented the progression of ventricular dilation and hypertrophy after TAC and halted the corresponding decline in ejection fraction. These beneficial effects were related to the attenuation of intracellular Ca2+ mishandling remodelling, antifibrotic and antihypertrophic effects and potentially antiarrhythmic effects by preventing the reduction of K+ current density and the long QT, JT and TpTe intervals observed in HF animals., [Conclusion and Implications]: The results suggest that paricalcitol treatment in established HF hampers disease progression and improves adverse electrophysiological and Ca2+ handling remodelling, attenuating the vulnerability to HF‐associated ventricular arrhythmias. Paricalcitol may emerge as a potential therapeutic option in the treatment of HF., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2014‐57190R and SAF2017‐84777‐R), Instituto de Salud Carlos III (ISCIII) (PI17/01093 and PI17/01344), European Regional Developmentc Fund (FEDER), Sociedad Española de Cardiología (SEC) and Centro de Investigación Biomédica en Red Cardiovascular (CIBER‐CV), a network funded by ISCIII. M.F.‐V. is a Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). G.R.‐H. is a Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). M.T. is a predoctoral fellow of the Spanish Ministry of Science, Innovation and Universities (Ministerio de Ciencia e Innovación) (FPU‐17/06135)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intracellular calcium mishandling leads to cardiac dysfunction and ventricular arrhythmias in a mouse model of propionic acidemia

  • Tamayo, María
  • Fulgencio-Covián, A.
  • Navarro-García, Jose A.
  • Val-Blasco, Almudena
  • Ruiz-Hurtado, Gema
  • Gil-Fernández, Marta
  • Martín-Nunes, Laura
  • Lopez, J. A.
  • Desviat, Lourdes R.
  • Delgado, Carmen
  • Richard, C.
  • Fernández-Velasco, María
Propionic acidemia (PA) is a rare metabolic disease associated with mutations in genes encoding the α and β subunits of the enzyme propionyl-CoA carboxylase. The accumulation of toxic metabolites results in mitochondrial dysfunction, increased reactive oxygen species production and oxidative damage, which have been associated with the disease pathophysiology. Clinical symptoms are heterogeneous and include cardiac complications, mainly cardiac dysfunction and arrhythmias, which are recognized as one of the major life-threatening manifestations in patients. We aimed to investigate the molecular mechanisms underlying the cardiac phenotype using a hypomorphic mouse model (Pcca−/−(A138T)) that recapitulates some biochemical and clinical characteristics of PA. We demonstrate that Pcca−/−(A138T) mice present with depressed cardiac function along with impaired cell contractility when compared to the wild-type mice. Cardiac dysfunction in Pcca−/−(A138T) mice was associated with lower systolic Ca2+ release ([Ca2+]i transients), impairment in the sarcoplasmic reticulum (SR) Ca2+ load and decreased Ca2+ re-uptake by SR-Ca2+ ATPase (SERCA2a). These functional changes correlated well with the depressed activity of SERCA2a, the elevated ROS levels and SERCA2a oxidation rate in cardiomyocytes isolated from Pcca−/−(A138T) mice. In addition, decreased SR-Ca2+ load in Pcca−/−(A138T) cardiomyocytes was associated with increased diastolic Ca2+ release. The increase in Ca2+ sparks, Ca2+ waves and spontaneous [Ca2+]i transients in Pcca−/−(A138T) cardiomyocytes could be responsible for the induction of ventricular arrhythmias detected in these mice. Overall, our results uncover the role of impaired Ca2+ handling in arrhythmias and cardiac dysfunction in PA, and identify new targets for the development of therapeutic approaches for this devastating metabolic disease., This work was supported by Spanish Ministry of Economy and Competitiveness and European Regional Development Fund (SAF2016-76004-R, SAF2017-84777-R and PGC2018-097019-B-I00), Instituto de Salud Carlos III (ISCIII) (PI17/01093, PI17/01344 and IPT17/0019 - ISCIII-SGEFI/ERDF, ProteoRed), European Regional Development Fund (FEDER), FSE, the Fundació Marató TV3 (grant 122/C/2015) and CIBERER and CIBER-CV, networks funded by ISCIII. Centro de Biología Molecular Severo Ochoa receives an institutional grant from Fundación Ramón Areces. The CNIC is supported by ISCIII, Spanish Ministry of Science, Innovation and Universities (MCIU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). MF-V is Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). GR-H is Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). MT is a PhD student funded by the FPU program of MCIU (FPU17/06135). AFC is a PhD student funded by the FPI-UAM program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic Deletion of NOD1 Prevents Cardiac Ca2+ Mishandling Induced by Experimental Chronic Kidney Disease

  • Gil-Fernández, Marta
  • Navarro-García, Jose A.
  • Val-Blasco, Almudena
  • González-Lafuente, Laura
  • Martinez, J. C.
  • Rueda, Angélica
  • Tamayo, María
  • Morgado, José Luis
  • Zaragoza, Carlos
  • Ruilope, Luis M.
  • Delgado, Carmen
  • Ruiz-Hurtado, Gema
  • Fernández-Velasco, María
© 2020 by the authors., Risk of cardiovascular disease (CVD) increases considerably as renal function declines in chronic kidney disease (CKD). Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) has emerged as a novel innate immune receptor involved in both CVD and CKD. Following activation, NOD1 undergoes a conformational change that allows the activation of the receptor-interacting serine/threonine protein kinase 2 (RIP2), promoting an inflammatory response. We evaluated whether the genetic deficiency of Nod1 or Rip2 in mice could prevent cardiac Ca2+ mishandling induced by sixth nephrectomy (Nx), a model of CKD. We examined intracellular Ca2+ dynamics in cardiomyocytes from Wild-type (Wt), Nod1−/− and Rip2−/− sham-operated or nephrectomized mice. Compared with Wt cardiomyocytes, Wt-Nx cells showed an impairment in the properties and kinetics of the intracellular Ca2+ transients, a reduction in both cell shortening and sarcoplasmic reticulum Ca2+ load, together with an increase in diastolic Ca2+ leak. Cardiomyocytes from Nod1−/−-Nx and Rip2−/−-Nx mice showed a significant amelioration in Ca2+ mishandling without modifying the kidney impairment induced by Nx. In conclusion, Nod1 and Rip2 deficiency prevents the intracellular Ca2+ mishandling induced by experimental CKD, unveiling new innate immune targets for the development of innovative therapeutic strategies to reduce cardiac complications in patients with CKD., This work was supported by Spanish Ministry of Economy and Competitiveness and European Regional Development Fund (SAF-2017-84777R), Institute of Health Carlos III (PI17/01093 and PI17/01344), Sociedad Española de Cardiología, Proyecto Traslacional 2019, Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Fondo Europeo de Desarrollo Regional (FEDER), FSE, and CIBER-CV, a network funded by ISCIII. M.F.-V. is Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). G.R.-H. is Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). M.T. is a PhD student funded by the FPU program of the Spanish Ministry of Science, Innovation and Universities (FPU17/06135). A.R. was supported by Fondo SEP-Cinvestav project #601410 FIDSC 2018/2; and Fondo SEP-Conacyt Ciencia Básica A1-S-9082.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ca2+ mishandling in heart failure: Potential targets

  • Val-Blasco, Almudena
  • Gil-Fernández, Marta
  • Rueda, Angélica
  • Pereira, Laetitia
  • Delgado, Carmen
  • Smani, Tarik
  • Ruiz-Hurtado, Gema
  • Fernández-Velasco, María
Ca2+ mishandling is a common feature in several cardiovascular diseases such as heart failure (HF). In many cases, impairment of key players in intracellular Ca2+ homeostasis has been identified as the underlying mechanism of cardiac dysfunction and cardiac arrhythmias associated with HF. In this review, we summarize primary novel findings related to Ca2+ mishandling in HF progression. HF research has increasingly focused on the identification of new targets and the contribution of their role in Ca2+ handling to the progression of the disease. Recent research studies have identified potential targets in three major emerging areas implicated in regulation of Ca2+ handling: the innate immune system, bone metabolism factors and post-translational modification of key proteins involved in regulation of Ca2+ handling. Here, we describe their possible contributions to the progression of HF., This work was supported by the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (SAF-2017-84777R), Institute of Health Carlos III (PI17/01093, PI20/01482 and PI17/01344), Sociedad Española de Cardiología, Proyecto Traslacional 2019, PI3110 Fundación Renal Íñigo Álvarez de Toledo (FRIAT), Fondo Europeo de Desarrollo Regional (FEDER), FSE, and CIBER-CV, a network funded by ISCIII. MF-V is Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). GR-H is Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). AR was supported by Fondo SEP-Cinvestav project # 601410 FIDSC 2018/2; and Fondo SEP-Conacyt Ciencia Básica A1-S-9082. LP is supported by Institut de France Bourse Lefoulon Delaland.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23

  • Navarro-García, Jose A.
  • Salguero, Rafael
  • González-Lafuente, Laura
  • Martín-Nunes, Laura
  • Rodríguez-Sánchez, Elena
  • Bada-Bosch, Teresa
  • Hernández, Eduardo
  • Mérida-Herrero, Evangelina
  • Praga, Manuel
  • Solís, Jorge
  • Arribas, Fernando
  • Bueno, Héctor
  • Kuro-o, Makoto
  • Fernández-Velasco, María
  • Ruilope, Luis M.
  • Delgado, Carmen
  • Ruiz-Hurtado, Gema
[Background]: Chronic kidney disease (CKD) is associated with increased propensity for arrhythmias. In this context, ventricular repolarization alterations have been shown to predispose to fatal arrhythmias and sudden cardiac death. Between mineral bone disturbances in CKD patients, increased fibroblast growth factor (FGF) 23 and decreased Klotho are emerging as important effectors of cardiovascular disease. However, the relationship between imbalanced FGF23-Klotho axis and the development of cardiac arrhythmias in CKD remains unknown. [Methods]: We carried out a translational approach to study the relationship between the FGF23–Klotho signaling axis and acquired long QT syndrome in CKD-associated uremia. FGF23 levels and cardiac repolarization dynamics were analyzed in patients with dialysis-dependent CKD and in uremic mouse models of 5/6 nephrectomy (Nfx) and Klotho deficiency (hypomorphism), which show very high systemic FGF23 levels. [Results]: Patients in the top quartile of FGF23 levels had a higher occurrence of very long QT intervals (> 490 ms) than peers in the lowest quartile. Experimentally, FGF23 induced QT prolongation in healthy mice. Similarly, alterations in cardiac repolarization and QT prolongation were observed in Nfx mice and in Klotho hypomorphic mice. QT prolongation in Nfx mice was explained by a significant decrease in the fast transient outward potassium (K+) current (Itof), caused by the downregulation of K+ channel 4.2 subunit (Kv4.2) expression. Kv4.2 expression was also significantly reduced in ventricular cardiomyocytes exposed to FGF23. Enhancing Klotho availability prevented both long QT prolongation and reduced Itof current. Likewise, administration of recombinant Klotho blocked the downregulation of Kv4.2 expression in Nfx mice and in FGF23-exposed cardiomyocytes. [Conclusion]: The FGF23–Klotho axis emerges as a new therapeutic target to prevent acquired long QT syndrome in uremia by minimizing the predisposition to potentially fatal ventricular arrhythmias and sudden cardiac death in patients with CKD., This work was supported by projects from the Instituto de Salud Carlos III, Ministry of Economy, Industry and Competitiveness (PI17/01093, PI17/01193, PI20/00763, CP15/00129, F18/00261, CPII20/00022, SAF2017-84777-R, PID2020-113238RB-I00), from the Sociedad Española de Cardiología (SEC), and from the Fundación Renal Íñigo Alvarez de Toledo (FRIAT), co-funded by the European Regional Development Fund (Fondos FEDER).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The aryl hydrocarbon receptor ligand FICZ improves left ventricular remodeling and cardiac function at the onset of pressure overload-Induced heart failure in mice

  • Tamayo, María
  • Martín-Nunes, Laura
  • Piedras, Maria J.
  • Martin-Calvo, María
  • Martí-Morente, Daniel
  • Gil-Fernández, Marta
  • Gómez-Hurtado, Nieves
  • Moro, María A.
  • Boscá, Lisardo
  • Fernández-Velasco, María
  • Delgado, Carmen
Adverse ventricular remodeling is the heart’s response to damaging stimuli and is linked to heart failure and poor prognosis. Formyl-indolo [3,2-b] carbazole (FICZ) is an endogenous ligand for the aryl hydrocarbon receptor (AhR), through which it exerts pleiotropic effects including protection against inflammation, fibrosis, and oxidative stress. We evaluated the effect of AhR activation by FICZ on the adverse ventricular remodeling that occurs in the early phase of pressure overload in the murine heart induced by transverse aortic constriction (TAC). Cardiac structure and function were evaluated by cardiac magnetic resonance imaging (CMRI) before and 3 days after Sham or TAC surgery in mice treated with FICZ or with vehicle, and cardiac tissue was used for biochemical studies. CMRI analysis revealed that FICZ improved cardiac function and attenuated cardiac hypertrophy. These beneficial effects involved the inhibition of the hypertrophic calcineurin/NFAT pathway, transcriptional reduction in pro-fibrotic genes, and antioxidant effects mediated by the NRF2/NQO1 pathway. Overall, our findings provide new insight into the role of cardiac AhR signaling in the injured heart., This research was supported by Grants SAF2017-84777-R, funded by the Ministry of Economy and Competitiveness (MINECO) of Spain, PID2020-113238RB-I00 funded by the Ministry of Science and Innovation (MCIN)/AEI/ 10.13039/501100011033 of Spain and the “European Union Next GenerationEU/PRTR”; PI20/01482-1 funded by the Instituto de Salud Carlos III, CB16/11/00222 funded by the Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV) and a Grant (Proyectos 2021) financed by the Universidad Francisco de Vitoria.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specialized proresolving mediators protect against experimental autoimmune myocarditis by modulating Ca2+ handling and NRF2 activation

  • Val-Blasco, Almudena
  • Prieto, Patricia
  • Iñigo Jaén, Rafael
  • Gil-Fernández, Marta
  • Pajares, Marta
  • Domenech, N.
  • Terrón, Verónica
  • Tamayo, María
  • Jorge, Inmaculada
  • Vázquez, Jesús
  • Bueno-Sen, A.
  • Vallejo-Cremades, Maria T.
  • Pombo-Otero, Jorge
  • Sánchez-García, Sergio
  • Ruiz-Hurtado, Gema
  • Gómez, Ana María
  • Zaragoza, Carlos
  • Crespo-Leiro, M. G.
  • López-Collazo, Eduardo
  • Cuadrado, Antonio
  • Delgado, Carmen
  • Boscá, Lisardo
  • Fernández-Velasco, María
Specialized proresolving mediators and, in particular, 5(S), (6)R, 7-trihydroxyheptanoic acid methyl ester (BML-111) emerge as new therapeutic tools to prevent cardiac dysfunction and deleterious cardiac damage associated with myocarditis progression. The cardioprotective role of BML-111 is mainly caused by the prevention of increased oxidative stress and nuclear factor erythroid-derived 2-like 2 (NRF2) down-regulation induced by myocarditis. At the molecular level, BML-111 activates NRF2 signaling, which prevents sarcoplasmic reticulum–adenosine triphosphatase 2A down-regulation and Ca2+ mishandling, and attenuates the cardiac dysfunction and tissue damage induced by myocarditis., This work was supported by the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (SAF-2017-84777R), Instituto de Salud Carlos III (ISCIII) (PI17/01093, PI17/01344, and PI20/01482), Sociedad Española de Cardiología, Proyecto Traslacional 2019 and Asociación del Ritmo Cardiaco (SEC, España), Proyecto Asociación Insuficiencia Cardiaca (Trasplante Cardiaco) 2020, Fondo Europeo de Desarrollo Regional, Fondo Social Europeo, and CIBERCV, a network funded by ISCIII, Spanish Ministry of Science, Innovation and Universities (PGC2018-097019-B-I00), Ministerio de Economía, Industria y Competitividad/Agencia Estatal de Investigación 10.13039/501100011033 PID2020-113238RB-I00, PID2019-105600RB-I00, the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria grant PRB3 [PT17/0019/0003-ISCIII-SGEFI/ERDF, ProteoRed]), and “la Caixa” Foundation (project code HR17-00247). The Centro Nacional de Investigaciones Cardiovasculares is supported by the ISCIII, the Ministerio de Ciencia, Innovación y Universidades. Dr Ruiz-Hurtado is Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). Dr Tamayo and R.I. Jaén, and M. Gil-Fernández were or currently are PhD students funded by the Formación de Profesorado Universitario program of the Spanish Ministry of Science, Innovation and Universities (FPU17/06135; FPU16/00827, FPU1901973).
Docta Complutense
Publicación Artículo científico (JournalArticle)

The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23

  • Navarro García, José Alberto
  • Salguero Bodes, Rafael
  • Praga Terente, Manuel
  • Arribas Ynsaurriaga, Fernando
  • Bueno Zamora, Héctor José
  • Ruilope Urioste, Luis Miguel
  • Ruiz Hurtado, Gema
Abstract Background: Chronic kidney disease (CKD) is associated with increased propensity for arrhythmias. In this context, ventricular repolarization alterations have been shown to predispose to fatal arrhythmias and sudden cardiac death. Between mineral bone disturbances in CKD patients, increased fibroblast growth factor (FGF) 23 and decreased Klotho are emerging as important effectors of cardiovascular disease. However, the relationship between imbalanced FGF23-Klotho axis and the development of cardiac arrhythmias in CKD remains unknown. Methods: We carried out a translational approach to study the relationship between the FGF23-Klotho signaling axis and acquired long QT syndrome in CKD-associated uremia. FGF23 levels and cardiac repolarization dynamics were analyzed in patients with dialysis-dependent CKD and in uremic mouse models of 5/6 nephrectomy (Nfx) and Klotho deficiency (hypomorphism), which show very high systemic FGF23 levels. Results: Patients in the top quartile of FGF23 levels had a higher occurrence of very long QT intervals (> 490 ms) than peers in the lowest quartile. Experimentally, FGF23 induced QT prolongation in healthy mice. Similarly, alterations in cardiac repolarization and QT prolongation were observed in Nfx mice and in Klotho hypomorphic mice. QT prolongation in Nfx mice was explained by a significant decrease in the fast transient outward potassium (K+) current (Itof), caused by the downregulation of K+ channel 4.2 subunit (Kv4.2) expression. Kv4.2 expression was also significantly reduced in ventricular cardiomyocytes exposed to FGF23. Enhancing Klotho availability prevented both long QT prolongation and reduced Itof current. Likewise, administration of recombinant Klotho blocked the downregulation of Kv4.2 expression in Nfx mice and in FGF23-exposed cardiomyocytes. Conclusion: The FGF23-Klotho axis emerges as a new therapeutic target to prevent acquired long QT syndrome in uremia by minimizing the predisposition to potentially fatal ventricular arrhythmias and sudden cardiac death in patients with CKD.